Liver MR relaxometry at 3T – segmental normal T₁ and T₂* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness

V. C. Obmann, N. Mertineit, C. Marx, A. Berzigotti, L. Ebner, J. T. Heverhagen, A. Christe & A. T. Huber

Magnetic resonance (MR) T₁ and T₂* mapping allows quantification of liver relaxation times for non-invasive characterization of diffuse liver disease. We hypothesized that liver relaxation times are not only influenced by liver fibrosis, inflammation and fat, but also by air in liver segments adjacent to the lung – especially in MR imaging at 3T. A total of 161 study participants were recruited, while 6 patients had to be excluded due to claustrophobia or technically uninterpretable MR elastography. Resulting study population consisted of 12 healthy volunteers and 143 patients who prospectively underwent multiparametric MR imaging at 3T. Of those 143 patients, 79 had normal liver stiffness in MR elastography (shear modulus < 2.8 kPa, indicating absence of fibrosis) and normal proton density fat fraction (pDFF < 10%, indicating absence of steatosis), defined as reference population. T₁ relaxation times in these patients were significantly shorter in liver segments adjacent to the lung than in those not adjacent to the lung (p < 0.001, mean of differences 33 ms). In liver segments not adjacent to the lung, T₁ allowed to differentiate significantly between the reference population and patients with steatosis and/or fibrosis (p ≤ 0.011), while there was no significant difference of T₁ between the reference population and healthy volunteers. In conclusion, we propose to measure T₁ relaxation times in liver segments not adjacent to the lung. Otherwise, we recommend taking into account slightly shorter T₁ values in liver segments adjacent to the lung.

Magnetic resonance (MR) imaging of the liver is a powerful tool in diagnosis of focal liver disease and is frequently used in clinical routine. Most conventional liver MR sequences measure relative signal intensities and therefore allow relative comparison between focal disease and adjacent normal hepatic parenchyma. However, detection and quantification of diffuse liver disease remains challenging but is desirable to avoid invasive and expensive biopsies.

Currently, existing non-invasive imaging biomarkers for diffuse liver disease include proton density fat fraction (PDFF) calculation and MR elastography. Another emerging technique is the quantification of T₁ relaxation time on parametric maps, which is routinely used in cardiac imaging, for example in diffuse cardiac fibrosis or myocarditis. Recently, the modified Look-Locker inversion recovery sequence (MOLLI) demonstrated great potential for application in diffuse liver disease.
### Table 1. Patient characteristics of the MR elastography study population (patients $n = 143$, volunteers $n = 12$, total $n = 155$). Values represent the mean ± SD or n. P-values were calculated using the Mann-Whitney U or Fisher’s exact test, as appropriate. Comparisons between the two patient groups with steatosis and the reference group in the first column are indicated with *p < 0.05; **p < 0.001. MR = magnetic resonance; PDFF = proton density fat fraction; BMI = body mass index; ASAT = aspartate aminotransferase; ALAT = alanine aminotransferase; GGT = gamma-glutamyltransferase; APRI = aspartate aminotransferase-to-platelet ratio index.

|                          | Reference population ($n = 79$) | Positive Controls 1 ($n = 23$) | p-value | Positive Controls 2 ($n = 26$) | Steatosis (PDFF > 10%) | Normal liver stiffness (shear modulus ≥ 2.8 kPa) | p-value | Positive Controls 3 ($n = 15$) | Steatosis (PDFF > 10%) | Increased liver stiffness (shear modulus ≥ 2.8 kPa) | p-value | Negative Controls ($n = 12$) Healthy Volunteers |
|--------------------------|---------------------------------|---------------------------------|---------|-------------------------------|------------------------|--------------------------------------------------|---------|-------------------------------|------------------------|--------------------------------------------------|---------|-----------------------------------------------|
| Age, years               | 51 ± 14                         | 59 ± 13                         | 0.023   | 56 ± 11                       | 57 ± 12                | 0.925                                            | 31 ± 9  |                                |                                       |                     |                                       |                     |                                |
| Male, %                  | 34 (43%)                        | 18 (78%)                        | 0.004   | 15 (58%)                      | 13 (87%)               | 0.084                                            | 7 (58%) |                                |                                       |                     |                                       |                     |                                |
| BMI, kg/m²               | 26 ± 8                          | 27 ± 6                          | 0.039   | 29 ± 5.5**                   | 31 ± 7                 | 0.559                                            | 22 ± 2  |                                |                                       |                     |                                       |                     |                                |
| Arterial hypertension   | 14 (18%)                        | 8 (35%)                         | 0.091   | 2 (8%)                       | 7 (47%)                | 0.006                                            | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| Dyslipidaemia            | 8 (10%)                         | 5 (22%)                         | 0.162   | 0 (0%)                       | 3 (20%)                | 0.043                                            | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| Diabetes Type 2          | 2 (3%)                          | 8 (35%)                         | 0.001   | 3 (12%)                      | 21 (13%)               | >0.009                                           | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| Chronic renal insufficiency | 1 (1%)                       | 1 (4%)                          | 0.402   | 0 (0%)                       | 0 (0%)                 | >0.009                                           | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| ≥1 medicament daily     | 20 (25%)                        | 12 (52%)                        | 0.021   | 6 (23%)                      | 6 (40%)                | 0.300                                            | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| ≥2 medicaments daily    | 5 (6%)                          | 8 (35%)                         | 0.001   | 2 (8%)                       | 4 (27%)                | 0.168                                            | 0 (0%)  |                                |                                       |                     |                                       |                     |                                |
| ASAT, U/I               | 24 ± 9                          | 39 ± 23                         | 0.029   | 29 ± 22                      | 47 ± 30                | 0.041                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| ALAT, U/I               | 30 ± 41                         | 36 ± 27                         | 0.003   | 34 ± 21                      | 55 ± 36                | 0.092                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| GGT, U/I                | 30 ± 33                         | 110 ± 143                       | <0.001  | 37 ± 22                      | 75 ± 67                | 0.224                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| Alkaline phosphatase, U/I| 73 ± 36                         | 87 ± 46                         | 0.107   | 78 ± 19                      | 88 ± 57                | 0.745                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| Bilirubin, μmol/l        | 10 ± 7                          | 19 ± 17                         | 0.016   | 8 ± 3                        | 18 ± 15                | 0.281                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| Albumin                 | 37 ± 3                          | 35 ± 4                          | 0.304   | 29 ± 15                      | 34 ± 5                 | 0.902                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| Quick, %                | 99 ± 3                          | 81 ± 20                         | <0.001  | 95 ± 8                       | 85 ± 23                | 0.601                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| APRI                    | 0.73 ± 1.61                     | 1.12 ± 1.00                     | 0.039   | 0.67 ± 0.74                  | 0.87 ± 1.15            | >0.009                                           | N/A     |                                |                                       |                     |                                       |                     |                                |
| Creatinine, μmol/l      | 78 ± 22                         | 76 ± 17                         | 0.792   | 84 ± 21                      | 82 ± 19                | 0.799                                            | N/A     |                                |                                       |                     |                                       |                     |                                |
| Combined: Diabetes, Dyslipidaemia, BMI > 25 | 1 (1%) | 2 (9%) | 0.127 | 0 (0%) | 2 (13%) | 0.128 |
| Combined: Smoking, Diabetes, Dyslipidaemia, BMI > 25 | 1 (1%) | 1 (4%) | 0.402 | 0 (0%) | 2 (13%) | 0.128 |

However, as known from cardiac applications, reference values should be established for different manufacturers, technical parameters and field strengths before using $T_1$ mapping in clinical routine. Further, it is known from cardiac imaging that $T_1$ values might be influenced if measured in the ventricle close to the lung, why usually measurements in the septum are preferred. Therefore, specific anatomical conditions of the liver with adjacent containing lungs and potential internal confounders, such as hepatic fat and iron composition, should be considered in hepatic $T_1$ mapping. We hypothesized that $T_1$ relaxation time is significantly shorter in liver segments adjacent to the lung than in liver segments not adjacent to the lung due to air-induced susceptibility effects at 3T.

### Results

#### Patient characteristics.

Patient characteristics are shown in Table 1. Patients without steatosis but with increased liver stiffness (shear modulus ≥ 2.8 kPa) showed a male predominance (78% males vs. 43% males in patients without fibrosis), a higher prevalence of diabetes (35% vs. 3%, p < 0.001), elevated GGT (110 ± 143 vs. 30 ± 33, p < 0.001), and prolonged extrinsic coagulation times (Quick 81 ± 20% vs. 99 ± 3%, p < 0.001). There was a tendency for more tobacco smokers in the group with increased liver stiffness, without statistical significance (p = 0.091). None of the patients was taking empagliflozin and only one patient was taking ezetimibe, both known to reduce liver fat as measured with PDFF.

#### Image quality.

Out of 143 patients and 12 volunteers, resulting in 155 participants, there was at least one segment of good diagnostic image quality in 152/155 participants (98%) for $T_1^*$, and in 149/155 participants (96%) for $T_1^*$ (Table 2). In the right liver, segments V-VIII were measurable in at least 90% of the patients for $T_1^*$. For $T_1^*$, the left liver segments were just measurable in 21–40%, while on the right side, the cranial right segments (VII and VIII) were measurable in 61–63% of patients and the right caudal segments (V and VI) were measurable in 86–88% of patients.

#### Location-based mapping results.

As shown in Table 3 and demonstrated in Fig. 1, $T_1$ values were significantly lower in the cranial slices than in the caudal slices (mean of the differences 33 ms, p < 0.001). This did
### Table 2. Mapping quality in different liver segments in all study participants (patients n = 143, volunteers n = 12, total n = 155). Values represent the numbers of participant with liver segments with good image quality on T\(_1\) and T\(_2^*\) maps, respectively. Relative portion compared to total study population (n = 155) is shown with the % shown in brackets. The first column indicates the number of participants with at least one segment with good image quality, followed by the number of participants with good image quality maps in Segment VI/VII, V/VIII, Iva/B and II/III, respectively. In the upper part of the Table results for T\(_1\), in the lower part results for T\(_2^*\) are described. P-values were calculated using Fisher’s exact test to compare the number of segments with good image quality at every localization to the number of at least one segment with good quality per patient.

| T\(_1\) | Segment VI/ VII | p-value | Segment V/ VIII | p-value | Segment Iva/b | p-value | Segment II/III | p-value |
|--------|-----------------|---------|-----------------|---------|---------------|---------|-----------------|---------|
| Upper level | VII/VIII/Iva/II | 140 (90%) | 0.006 | 143 (92%) | 0.031 | 135 (87%) | <0.001 | 134 (86%) | <0.001 |
| Lower level | VI/V/Ivb/III | 140 (90%) | 0.006 | 147 (95%) | 0.218 | 102 (66%) | <0.001 | 88 (57%) | <0.001 |
| T\(_2^*\) | All segments | 149/155 (96%) | | | | | | | |
| Upper level | VII/VIII/Iva/II | 95 (61%) | <0.001 | 97 (63%) | <0.001 | 62 (40%) | <0.001 | 58 (37%) | <0.001 |
| Lower level | VI/V/Ivb/III | 137 (88%) | 0.018 | 134 (86%) | 0.004 | 58 (37%) | <0.001 | 33 (21%) | <0.001 |

### Table 3. Reference values in different liver segments in patients with normal liver stiffness without steatosis (n = 79). Values represent the mean ± SD or n. P-values were calculated using a paired Mann-Whitney U test to compare upper and lower levels and each liver segment with the mean value of all liver segments of the same level: *p < 0.05; **p < 0.001.

| T\(_1\) | All liver segments | N | Segment VI/ VII | N | Segment V/ VIII | N | Segment Iva/b | N | Segment II/III | N |
|--------|-------------------|---|-----------------|---|-----------------|---|---------------|---|---------------|---|
| Upper level | VII/VIII/Iva/II | 751 ± 82 ms | 78 | 742 ± 82 ms* | 72 | 744 ± 84 ms* | 76 | 752 ± 86 ms | 72 | 770 ± 87 ms** | 67 |
| Lower level | VI/V/Ivb/III | 781 ± 84 ms | 77 | 776 ± 85 ms* | 73 | 785 ± 89 ms | 76 | 775 ± 110 ms | 61 | 776 ± 83 ms | 43 |
| Mean of the differences | 33 ms | 34 ms | 42 ms | 27 ms | 6 ms |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 | 0.365 |
| T\(_2^*\) | All segments | 20 ± 5 ms | 76 | 18 ± 6 ms | 60 | 18 ± 5 ms* | 50 | 18 ± 6 ms | 49 | 21 ± 7 ms** | 33 |
| Upper level | VII/VIII/Iva/II | 19 ± 6 ms | 60 | 18 ± 6 ms | 50 | 18 ± 5 ms* | 49 | 18 ± 6 ms | 49 | 21 ± 7 ms** | 33 |
| Lower level | VI/V/Ivb/III | 20 ± 5 ms | 75 | 20 ± 5 ms | 68 | 20 ± 5 ms | 67 | 20 ± 6 ms | 67 | 19 ± 6 ms | 30 |
| Mean of the differences | 0.9 ms | 1.7 ms | 1.6 ms | 0.6 ms | −0.9 ms |
| P-value | 0.013 | <0.001 | <0.001 | 0.567 | 0.082 |

### Discussion

This study shows that T\(_1\) relaxation time is significantly shorter in liver segments adjacent to the lung than in liver segments not adjacent to the lung. We calculated a mean T\(_1\) value of 780 ± 83 ms at 3T in liver segments not adjacent to the lung (segments II, III, Ivb, V, VI), while T\(_1\) was around 30 ms shorter in liver segments adjacent to the lung (segments Iva, VII, VIII) in a patient population, without focal (based on CT) or diffuse (based on PDFF and MR elastography) liver disease.

---

**Inter-reader reliability.** The ICC values were excellent for both T\(_1\) and T\(_2^*\), as measured in segment VI. The ICC was 0.97 (95%-CI: 0.91–0.99) for T\(_1\) and 0.91 (95%-CI: 0.78–0.97) for T\(_2^*\).
This difference may be explained by different reasons. One possibility are susceptibility effects from adjacent air in the lungs. Susceptibility differences between liver and lungs cause off-resonance, which may lead to $T_1$ underestimation. Similar effects are known from myocardial $T_1$ mapping\textsuperscript{20,21}. In addition, there is a $T_2$-dependency of the MOLLI based $T_1$ mapping sequence due to its bSSFP design, therefore influencing the measured $T_1$ value. Another explanation might be partial volume effects at the liver dome since the slice thickness is 10 mm (Fig. 4), which is also known from neuroimaging\textsuperscript{22}. However, the regions of interests (ROI) were drawn carefully to exclude liver vessels and outer 10 mm of the liver border, to prevent this possible bias as much as possible.

While differences between cranial and caudal segments in the right liver lobe and segment IVa vs. IVb were comparable, the $T_1$ relaxation time difference between segment II and III was smaller. A potential explanation for this different behaviour might be that segment II is in close anatomical neighborhood to the heart and not to the lungs as the cranial segments VII, VIII and IVa are. We therefore propose to measure $T_1$ relaxation time in liver segments V and VI with excellent inter-reader-reliability, when a representative $T_1$ quantification of the liver is intended. These segments are normally targeted for liver biopsy and may be regarded as representative for the whole liver. However, for a more detailed segmental analysis of $T_1$ relaxation times in the liver shorter normal $T_1$ values in liver segments adjacent to the lung should be taken into account. $T_2^*$ seems to be more prone to respiratory and pulsation artefacts from the beating heart, which might explain lower image quality in segments of the left liver lobe (adjacent to the heart) and in cranial segments, while image quality in caudal left segment V and VI showed the best image quality. Electrocardiography gating might improve image quality, which was not tested in this study.

Figure 1. $T_2^*$ and $T_1$ mapping in a reference patient (male, 73 years old). Parametric maps with $T_2^*$ on the left and $T_1$ on the right are presented, from cranial (top) to caudal slices (bottom). Note the lower $T_2^*$ values (blue) in cranial segments VII, VIII and IVa compared to the middle and lower slice (red) showing segments VI, V, IVb and III.
There are very few published data on normal T1 values of the liver at 3T using the MOLLI technique. Katsube et al. presented a mean value of 836 ± 69 ms in 16 patients with normal liver function. The slightly lower values in our study (780 ± 83 ms in reference patients, 799 ± 59 ms in healthy volunteers) may be explained by a smaller population in the study of Katsube et al., as well as by the fact that Katsube et al. defined the normal population based on normal liver function in laboratory tests, which does not exclude patients with steatosis or early liver fibrosis. Other published normal T1 values were generated with other mapping techniques, but are nevertheless in a similar range, such as 824 ± 61 ms in 26 healthy volunteers using a spiral GRAPPA-based method, 825 ± 49 ms in 6 healthy volunteers.

Table 4. T1 values of lung-adjacent and non-lung-adjacent liver segments in all study participants (patients n = 143, volunteers n = 12, total n = 155). Values represent the mean ± SD or n. P-values were calculated using the Mann-Whitney U test, *compared to patients with normal liver stiffness without steatosis, **compared to patients with normal liver stiffness with steatosis.
volunteers using an inversion recovery method with refocusing pulses, and 745 ± 65 ms in 8 healthy volunteers using MR fingerprinting. Slight differences might be explained by different techniques of assessment and small sample sizes used in the cited studies. This underlines the recommendation, that normative values should be established for the particular site and set-up for different manufacturers, technical parameters and field strengths before using T1 mapping in clinical routine. In accordance with other published studies, increased T1 time correlated with increased liver stiffness in MR elastography as a non-invasive surrogate for liver fibrosis. Yoon et al. published T1 values in patients with chronic liver disease (863 ± 81 ms) and Child A liver cirrhosis (879 ± 86 ms) in the same range as we present here (849 ± 107 ms for early liver fibrosis and 910 ± 98 ms for significant fibrosis). T1 values calculated with commercially available software solutions using the MOLLI mapping technique have been shown to correlate with the severity of NAFLD/NASH and fibrosis and may predict clinical outcome in these patients. We demonstrated an increased T1 time in patients with steatosis, which is in accordance with other published studies. This is a paradox, since fat has a much shorter T1 time than water. According to recent publications, off-resonance effects in imaging voxels containing a mixture of fat and water signals may explain this finding.

In addition to fat and fibrosis content as well as susceptibility-effects in liver segments adjacent to the lung, there are several other potential confounders of T1 and T2*. One known confounder inducing T1 shortening is liver iron content, however patients with iron overload have been excluded in this study. Liver blood distribution and oxygenation levels are might influence T1 and T2* times as well. These effects and possible influences on T1 and T2* need further investigation. In multivariate analysis of reference patients without focal or diffuse liver disease and healthy volunteers, we could not demonstrate a significant age- or sex- dependency of the measured T1 values. However, there was a collinearity between T1 and T2* values. Further research should be performed to show whether T1 is T2* dependent (e.g. due to fat, iron composition, blood distribution and eventually blood oxygenation influencing T2*) or whether it is the other way round and T2* is influenced by T1 due to a too short TR in the used T2*-mapping sequence. Also using a multiparametric approach combining T1, T2*, MRE and PDFF might deliver further insights. Our study highlights the importance of standardized technical parameters and well-defined normal values when performing T1 mapping of the liver. For an accurate non-invasive characterization of diffuse liver disease, a combined analysis of different MR parameters such as T1 mapping, T2* mapping, elastography and PDFF should be performed. Further research will show how a multiparametric combination of those MR imaging biomarkers may help differentiating and quantifying diffuse liver disease.

Limitations. Our study has several limitations. First, we focused on a population without known chronic liver disease. Due to the study design and associated ethical considerations, liver biopsy was not possible. Instead, we used MR elastography and PDFF, which have been shown to correlate very well with biopsy-confirmed fibrosis and steatosis grades, as the non-invasive gold standard, and we included negative and positive controls based on these imaging techniques. Another limitation is that we did not obtain full 3D coverage of the liver, as we used commercially available Siemens MOLLI sequences with 2D acquisitions on three transverse slices. Nevertheless, we present a segmental comparison of T1 mapping in a reference population, as well as in negative and positive controls. Newer 3D mapping sequences or MR fingerprinting may offer even more applications for future use.

Conclusion

When analysing T1 maps in the liver at 3T, we propose to measure T1 relaxation times in liver segments not adjacent to the lung. Otherwise, we recommend taking into account slightly shorter T1 normal values in liver segments adjacent to the lung.
Methods

Study population. This prospective cross-sectional study was approved by the institutional review board (Kantonale Ethikkommission Bern, IRB number 282–15) and was conducted in accordance with relevant guidelines and regulations after obtaining written patient informed consent. All participants underwent multiparametric MR imaging at 3T in our institution between 03/2016–06/2017, including T1 and T2* mapping, proton density fat fraction (PDFF) quantification and MR elastography.

A total of 161 study participants were recruited, while 6 patients had to be excluded due an incomplete MR exam due to claustrophobia or technically uninterpretable MR elastography. Resulting study population consisted of twelve healthy volunteers without a history of liver disease (negative controls) and 143 patients (Fig. 5). The included 143 patients were selected based on acquired abdominal computed tomography (CT) scans without focal liver disease (cysts > 2 cm, solid lesion > 1, prior liver surgery). Out of the 143 patients, we then defined a reference population (n = 79) without focal (based on CT) or diffuse liver disease (based on MR elastography shear modulus < 2.8 kPa and PDFF < 10%). CT scans in the reference population were performed with following indications: trauma (n = 14), abdominal pain (n = 19), infection (n = 23) and tumor search (n = 23). The remaining patients (n = 64) were assigned to positive control groups with diffuse liver disease (MR elastography shear modulus ≥ 2.8 kPa and/or PDFF ≥ 10%).

Clinical information and laboratory test results were recorded for the included patients. Clinical parameters included age, gender, body mass index (BMI), history of diabetes or hypertension, daily drug intake, tobacco use and alcohol consumption. Biological parameters included dyslipidemia, platelet count, quick value, total bilirubin levels, gamma-glutamyltranspeptidase (GGT), aspartateaminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, albumin, creatinine and hematocrit.

Sample size estimation. To detect a mean difference in T1 of 5% (=40 ms) between the upper and lower liver segments with a significance level of 0.05 and a power of 0.8, a sample size of 72 was needed. A mean T1 time of 800 ms with standard deviation of 85 ms was based on a pilot readout for sample size calculations.

MR imaging technique. Patients were examined with a 3T-MR system (Verio, Siemens Healthineers) in a fasting state (>6h). For T1 mapping, we used an axial-acquired, MOLLI single breath-hold sequence (echo time (TE) of 1.01 ms, data acquisition window of 740 ms, inversion time (TI) 225 ms (3 inversion pulses, starting at 65 ms with an increment of 80 ms), flip angle (FA) 35°, 8-mm slice thickness, field-of-view (FOV) 384, matrix 154 × 192 pixels, and scan time of 11 s) with a 3-3-5 design (acquisition during 3 heartbeats, pause during 3 heartbeats for relaxation purposes and acquisition during another 5 heartbeats). T2* mapping was performed...

Figure 4. Localization of acquired maps. Correlation of T2* maps (B,E), T1 maps (C,F) and coronal T2w HASTE images (A,D) for two patients are shown. The yellow box in displays A and D indicate the location of the 10 mm thick mapping slices. The green lines show the area with lower relaxation times and their distance from the liver border. The red lines demonstrate the distance from there to the liver dome. In the patient in the upper row (A–C), a 67-year-old man, partial volume is a good explanation for shorter relaxation times with obvious artefacts in Segment VII on the T1 map (C), while in the other patient (D–F), a 30-year-old women, shorter relaxation times cannot be explained by partial volume alone. Although patient might have shown different breathing between coronal and axial sequences, no significant difference in acquisition level is to assume since the stomach is still seen on axial slices.
with a multiecho gradient echo (GRE) single breath-hold sequence (12 echoes with a TE between 0.93–14.2 ms, TR of 200 ms, FA 18°, FOV 400, 10-mm slice thickness, and scan time of 19 s). T1 and T2* maps were generated on three single slices in the upper, mid and lower liver. PDFF was calculated using the Dixon method with axial T1-weighted axial vibe images (TE of 2.45 ms and 3.68 ms, TR of 5.47 ms, FA 9°, 3-mm slice thickness, and scan time of 22 s) to differentiate patients with and without liver steatosis. For MR elastography, a pneumatic driver (Resoundant) was placed on the right upper quadrant transmitting shear waves by continuous acoustic vibrations with a frequency of 60 Hz. The liver shear stiffness in kPa in the right upper liver lobe was determined with a gradient echo-based elastography sequence (WIP package 622 provided by Siemens Healthineers, 3 single-slice acquisitions with 5-mm slice thicknesses) using the 95% confidence map of stiffness. A shear modulus ≥2.8 kPa was considered to represent early liver fibrosis (corresponding to histology fibrosis grade ≥F1, according to the Metavir staging system), while a shear modulus ≥3.5 kPa was defined as significant liver fibrosis (corresponding to histology fibrosis grade ≥F3).8,36,37.

MR imaging analysis. Prior to any measurements image quality on relaxometry maps was assessed by an experienced radiologist (V.O., 5 years of experience in hepatic imaging). For T1 and T2* mapping, 8 polygonal regions of interest (ROI) were drawn in liver segments II–VIII by the radiologist (V.O.) who was blinded to the patient’s clinical history. In liver segments without excellent image quality (e.g. due to motion artefacts) or in segments that were not captured on any of the three acquired slices, no ROI was drawn at this location, and thus no value was assigned to the respective segment. The mean ROI size was 685 ± 203 mm². Large blood vessels, bile ducts and regions with partial volume, including air or perihepatic fat at the liver border, were excluded (Fig. 6). Another radiologist (A.H.), who was blinded to the patient’s clinical history and had 7 years of experience in hepatic imaging, measured the shear modulus (in kPa) on MR elastography images and the PDFF (in %) based on in- and out-of-phase DIXON images in the right liver on three slices, using polygonal ROIs to exclude vessels and partial volume at the liver borders. The median value of the three ROIs was then calculated.

Statistical analysis. Analysis was performed with the statistical software package R (version 3.4.1, R Foundation for Statistical Computing)38 and GraphPad Prism (version 7.1, GraphPad Software Inc.). Clinical characteristics were compared between groups using the Wilcoxon test for continuous variables or Fisher’s exact test for categorical variables. The p-value for significance was <0.05. T1 and T2* mapping parameters with good quality were then compared between segments using a paired Wilcoxon test. To address intersegmental variability and to identify the best area for reference, the median values of the liver segments adjacent to the lung (VII, VIII, IVa) and those not adjacent to the lung (VI, V, IVb, II, III) were calculated for the reference population and compared with the negative and positive controls using the Wilcoxon test.

To assess possible confounders in the reference population and among healthy volunteers (n = 79 + 12), a multivariate regression model was used with T1 (segments not adjacent to the lung) as the outcome and sex (dummy-coded), age, PDFF and T2* (segments not adjacent to the lung) as variables. Age and sex were chosen as basic demographic characteristics that might bias the measured T1 in the liver while PDFF and T2* were added as known representatives of liver fat and iron content that might influence T1. Pearson correlation was used to

Figure 5. Study participant workflow. A total of 161 participants were recruited for the study. Six patients were excluded because of an aborted MRI scan due to claustrophobia (n = 1) or due to technically inadequate MRE scans (n = 5). Resulting included study population consisted of 12 healthy volunteers with normal liver stiffness and without steatosis (negative controls) and 143 patients without focal liver disease on CT. The MRI scans of 143 patients were included in statistical analysis. There were 102 patients who did not show steatosis, and 79 of these 102 patients also showed normal liver stiffness (reference patients). The remaining 23 showed increased liver stiffness (≥2.8 kPa). Forty-one patients had liver steatosis with PDFF > 10% (26 with normal liver stiffness, 15 with increased liver stiffness). Patients with increased liver stiffness and/or steatosis were defined as positive controls.
compare MR elastography shear modulus with $T_1$ values. For interrater reliability, $T_1$ and $T_2^*$ relaxation time was measured in segment VI in 20 randomly selected consecutive patients by a second radiologist (A.H.), who was blinded to the patient’s clinical history and had 7 years of experience in hepatic imaging. The two-way consistency intraclass correlation (ICC) was then calculated and classified as follows: ICC 0.4–0.59 defined as fair; 0.6–0.74 defined as good; and 0.75–1.00 defined as excellent39.

**Human subject research.** This prospective cross-sectional study was approved by the institutional review board (IRB number 282-15) and was conducted after obtaining written patient informed consent.

**Data Availability**

Data generated for analysis during this study are included in this published article. Original patient data files are precluded from dissemination following Swiss Federal Law regulations (https://www.admin.ch/opf/officialcompilation/2013/3381.pdf). Data requests may be sent to: Kantonale Ethikkommission für die Forschung Murtenstrasse 31, 3010 Bern (Tel. +41 31 633 70 70, Fax +41 31 633 70 71, info.kek.kapa@gef.be.ch).

**References**

1. Bartolozzi, C. MR of the liver: from breakthrough to clinical application. *Abdom Imaging* 37, 154, https://doi.org/10.1007/s00261-011-9773-2 (2012).
2. Hoad, C. L. et al. A study of $T(1)$ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. *NMR in biomedicine* 28, 706–714, https://doi.org/10.1002/nbm.3299 (2015).
3. Matos, A. P. et al. Focal liver lesions: Practical magnetic resonance imaging approach. *World journal of hepatology* 7, 1987–2008, https://doi.org/10.4254/wjh.v7.i16.1987 (2015).
4. Unal, E., Ildiman, I. S. & Karcaaltincaba, M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. *Expert review of gastroenterology & hepatology* 11, 167–182, https://doi.org/10.1080/17474124.2017.127170 (2017).
5. Dilliman, J. R. et al. Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other? *AJR. American journal of roentgenology* 210, 166–174, https://doi.org/10.2214/ajr.17.18446 (2018).
6. Hong, C. W. et al. MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis. *Journal of magnetic resonance imaging: JMRI*, https://doi.org/10.1002/jmri.25845 (2017).
7. Morisaka, H. et al. Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging. *Journal of magnetic resonance imaging: JMRI*, https://doi.org/10.1002/jmri.25868 (2017).
8. Srinivasa Babu, A. et al. Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. *Radiographics: a review publication of the Radiological Society of North America, Inc* 36, 1987–2006, https://doi.org/10.1148/rg.2016160042 (2016).
9. Spiewak, M. T1 and T2 Mapping: The Next Giant Leap in Cardiac Imaging. *Cardiology* 138, 264–266, https://doi.org/10.1159/000479583 (2017).
10. Nakamori, S. et al. Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy. *JACC. Cardiovascular imaging* 11, 48–59, https://doi.org/10.1016/j.jcmg.2017.04.006 (2018).
11. Moon, J. C., Treibel, T. A. & Schelbert, E. B. T1 mapping for diffuse myocardial fibrosis: a key biomarker in cardiac disease? *Journal of the American College of Cardiology* 62, 1288–1289, https://doi.org/10.1016/j.jacc.2013.05.077 (2013).
12. von Knobelsdorff-Brenkenhoff, F. et al. Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance. *Circulation. Cardiovascular imaging* 10, https://doi.org/10.1161/circimaging.116.005242 (2017).
Banerjee, R. et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. *Journal of hepatology* **60**, 69–77, https://doi.org/10.1016/j.jhep.2013.09.002 (2014).

Heye, T. et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. *European radiology* **22**, 1224–1232, https://doi.org/10.1007/s00330-012-2378-5 (2012).

Moon, J. C. et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. *Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance* **15**, 92, https://doi.org/10.1186/1532-429X-15-92 (2013).

Bulluck, H. et al. Myocardial T1 mapping. *Circulation journal: official journal of the Japanese Circulation Society* **79**, 487–494, https://doi.org/10.1253/circji.CJ-15-0054 (2015).

Kawel, N. et al. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. *Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance* **14**, 27, https://doi.org/10.1186/1532-429X-14-27 (2012).

Kuchay, M. S. et al. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). *Diabetes care* **41**, 1801–1808, https://doi.org/10.2337/dc18-0165 (2018).

Loomba, R. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. *Journal of hepatology* **68**, 296–304, https://doi.org/10.1016/j.jhep.2017.11.028 (2018).

Punthmann, V. O., Peker, E., Chandrashhekar, Y. & Nagel, E. T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. *Circulation research* **119**, 277–299, https://doi.org/10.1161/circresaha.116.307974 (2016).

Weingartner, S. et al. Myocardial T1-mapping at 3T using saturation-recovery: reference values, precision and comparison with MOLLI. *Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance* **18**, 84, https://doi.org/10.1186/s12968-016-0302-x (2016).

Tunnicliffe, E. M. et al. Magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. *Liver international: official journal of the International Association for the Study of the Liver* **37**, 1065–1073, https://doi.org/10.1111/liv.13284 (2017).

Pavlides, M. et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. *Liver international: official journal of the International Association for the Study of the Liver* **37**, 308–315, https://doi.org/10.1111/liv.13097 (2016).

Katsube, T. Partial volume effect modeling for segmentation and tissue classification of brain magnetic resonance images: A review. *World journal of radiology* **6**, 855–864 (2014).

Katsube, T. et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. *Investigative radiology* **46**, 277–283, https://doi.org/10.1097/RLI.0b013e31820067d4 (2011).

Chen, Y. et al. Rapid volumetric T1 mapping of the abdomen using three-dimensional through-time spiral GRAPPA. *Magnetic resonance in medicine* **75**, 1457–1465, https://doi.org/10.1002/mrm.25693 (2016).

Ding, Y. et al. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. *European radiology* **24**, 959–966, https://doi.org/10.1007/s00330-014-3096-y (2014).

Chen, Y. et al. MR Fingerprinting for Rapid Quantitative Abdominal Imaging. *Radiology* **279**, 278–286, https://doi.org/10.1148/ radiol.2016152037 (2016).

Yoon, J. H., Lee, J. M., Paek, M., Han, J. K. & Choi, B. I. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. *European radiology* **26**, 1775–1782, https://doi.org/10.1007/s00330-015-3994-7 (2016).

Pavlides, M. et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. *Liver international: official journal of the International Association for the Study of the Liver* **37**, 1065–1073, https://doi.org/10.1111/liv.13284 (2017).

Pavlides, M. et al. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. *Journal of hepatology* **64**, 308–315, https://doi.org/10.1016/j.jhep.2015.10.009 (2016).

Henninger, B. et al. Die MRT mit T1- und T2*-Mapping zur Verifizierung einer Steatosis Hepatis - ein Vergleich mit In-Phase und Opposed-Phase-Sequenzen. *RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren* **183**, W3_P014 https://doi.org/10.1055/s-0033-1279566 (2011).

Moze, F. E., Tunnichlfe, E. M., Pavlides, M. & Robson, M. D. Influence of fat on liver T1 measurements using modified Look-Locker inversion recovery (MOLLI) method at 3T. *Journal of magnetic resonance imaging: JMRI* **44**, 105–111, https://doi.org/10.1002/jmri.25146 (2016).

Thießen, S. B., Thompson, R. B. & Chow, K. Characterization of T1 bias from lipids in MOLLI and SASHA pulse sequences. *Journal of cardiovascular magnetic resonance: official journal of the Society for Cardiovascular Magnetic Resonance* **17**, W10, https://doi.org/10.1186/1532-429X-17-s1-w10 (2015).

Tunnichlfe, E. M., Banerjee, R., Pavlides, M., Neubauer, S. & Robson, M. D. A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 in hepatic fibrosis. *Magnetic resonance imaging: JMRI* **45**, 450–462, https://doi.org/10.1002/mrx2.25392 (2017).

Yin, M. et al. Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations. *Radiology* **278**, 114–124, https://doi.org/10.1148/radiol.2015142141 (2016).

Permutt, Z. et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. *Aliment Pharmacol Ther* **36**, 22–29, https://doi.org/10.1111/apt.13650.2015.2016.05121.x (2012).

Singh, S. et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association* **13**, 440–451.e446, https://doi.org/10.1016/j.cgh.2014.09.046 (2015).

Singh, S. et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. *European radiology* **26**, 1431–1440, https://doi.org/10.1007/s00330-015-3949-2 (2016).

R. Core Team. *R language definition*. (R Foundation for Statistical Computing, 2000).

Cicchetti, D. V. *Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology*. *Psychol Assess* **6**, 284 (1994).

**Acknowledgements**

This work was supported by the Swiss National Science Foundation Research Equipment (R’Equip Grant) and Matching Fund from the University of Bern as well as the foundation to fight against cancer. The authors thank the highly motivated MR imaging technicians and image core lab team from the Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital for their support, especially V. Beutler-Minth, Sarah Gfeller, Michelle Schweizer, Géraldine Gemmet, Sandra Feller and Domenica Antosz-Bortoluzzi, as well as Kathrin Dopke from our study coordination division. We thank Siemens for providing access to the MR elastography sequence (WIP622).
Author Contributions
All authors contributed significantly to this manuscript. V.C.O., A.C. and A.T.H. study concepts/study design. V.C.O., A.T.H., A.C., N.M. and C.M. data acquisition or data analysis/interpretation. All authors: manuscript drafting or manuscript revision for important intellectual content. All authors: approval of final version of submitted manuscript. All authors: literature research.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019